- Trials with a EudraCT protocol (607)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
607 result(s) found for: Lymphoid Cell.
Displaying page 1 of 31.
EudraCT Number: 2012-001768-31 | Sponsor Protocol Number: ZENO-01 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: MALT Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004289-42 | Sponsor Protocol Number: ZENO-06021957 | Start Date*: 2008-03-20 | |||||||||||
Sponsor Name:National and Kapodistrian University of Athens | |||||||||||||
Full Title: 90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000767-41 | Sponsor Protocol Number: AGMT_MALT | Start Date*: 2008-04-30 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) | |||||||||||||
Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004896-38 | Sponsor Protocol Number: IELSG38 | Start Date*: 2014-02-13 | |||||||||||
Sponsor Name:IELSG (International Extranodal Lymphoma Study Group) | |||||||||||||
Full Title: A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF ... | |||||||||||||
Medical condition: Patients with MALT Lymphoma treated with chlorambucil and rituximab followed by maintenance treatment with subcutaneous rituximab | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005818-10 | Sponsor Protocol Number: AGMT_MALT-2 | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) | |||||||||||||
Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002596-10 | Sponsor Protocol Number: INCB54828-203 | Start Date*: 2017-01-30 |
Sponsor Name:Incyte Corporation | ||
Full Title: A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement | ||
Medical condition: Lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) AT (Completed) ES (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000327-18 | Sponsor Protocol Number: CLL 2007 FMP | Start Date*: 2007-07-06 | |||||||||||
Sponsor Name:GOELAMS | |||||||||||||
Full Title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previo... | |||||||||||||
Medical condition: Rituximab and Campath are two antibodies directed against CD20 and CD52 antigen, respectively. The highest response rate in the B-CLL treatment has been obtained by the association of Fludarabine,... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003038-17 | Sponsor Protocol Number: CART19-BE-02 | Start Date*: 2020-09-18 | |||||||||||
Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) | |||||||||||||
Full Title: Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity... | |||||||||||||
Medical condition: CD19+ acute lymphoid leukemia resistant or refractory to treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007725-39 | Sponsor Protocol Number: MALT2008-01 | Start Date*: 2009-05-05 | |||||||||||
Sponsor Name:Fundación GEL/TAMO | |||||||||||||
Full Title: ESTUDIO MULTICENTRICO FASE II, NO ALEATORIZADO, DE RITUXIMAB EN COMBINACIÓN CON BENDAMUSTINA COMO PRIMER TRATAMIENTO SISTÉMICO EN LINFOMA DE CÉLULAS B DE LA ZONA MARGINAL EXTRAGANGLIONAR DEL TEJID... | |||||||||||||
Medical condition: Linfoma no hodgkiniano marginal de tipo MALT en una primera línea de inmunoquimioterapia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000159-14 | Sponsor Protocol Number: CLL1818 | Start Date*: 2019-09-17 | ||||||||||||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||||||||||||
Full Title: Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemot... | ||||||||||||||||||||||||||||
Medical condition: Chronic lymphocytic leukemia is a neoplasm of the lymphatic system characterized by an accumulation of B lymphocytes in peripheral blood, bone marrow and lymphatic organs. Diffuse Large Cell B Lymp... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000860-28 | Sponsor Protocol Number: 02CLLIII | Start Date*: 2004-12-02 | |||||||||||
Sponsor Name:ribosepharm GmbH | |||||||||||||
Full Title: PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY | |||||||||||||
Medical condition: Hematopoietic insufficiency with non-hemolysis-induced Hb <10 g/dL Thrombocytopenia <100x109/L (equivalent to Binet stage C) B symptoms Rapidly progressive disease (such as rapid lymphoma growth, r... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003079-32 | Sponsor Protocol Number: CC-5013-CLL-008 | Start Date*: 2009-06-19 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LÍNEA EN PA... | |||||||||||||
Medical condition: TERAPIA DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B NO TRATADOS PREVIAMENTE (FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRON... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002987-24 | Sponsor Protocol Number: 152CL201 | Start Date*: 2007-06-25 | |||||||||||
Sponsor Name:Biogen Idec Ltd | |||||||||||||
Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho... | |||||||||||||
Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006694-24 | Sponsor Protocol Number: IV-A05-LL-01-PR.03 | Start Date*: 2007-07-16 | |||||||||||
Sponsor Name:Fresenius Biotech GmbH | |||||||||||||
Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia | |||||||||||||
Medical condition: relapsed or refractory Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017449-72 | Sponsor Protocol Number: 1840 | Start Date*: 2010-01-14 | |||||||||||
Sponsor Name:FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN | |||||||||||||
Full Title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukem... | |||||||||||||
Medical condition: Patients with Advanced Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018519-14 | Sponsor Protocol Number: IEO S523/110 | Start Date*: 2011-01-13 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | |||||||||||||
Medical condition: CHRONIC LYMPHATIC LEUKEMIA, LYMPHOCYTIC LYMPHOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005399-12 | Sponsor Protocol Number: DKMS-16-01 | Start Date*: 2017-08-02 | ||||||||||||||||||||||||||
Sponsor Name:DKMS gemeinnützige GmbH | ||||||||||||||||||||||||||||
Full Title: A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor | ||||||||||||||||||||||||||||
Medical condition: Patients with high-risk AML, ALL or MDS which have to undergo allogenic transplantaion. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001015-28 | Sponsor Protocol Number: LLC 2007 SA | Start Date*: 2007-07-27 | |||||||||||
Sponsor Name:CHU TOURS | |||||||||||||
Full Title: Single-agent rituximab as maintenance treatment versus observation after combined induction immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years... | |||||||||||||
Medical condition: The trial compares single-agent rituximab as maintenance treatment versus observation after combined immunochematherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011225-14 | Sponsor Protocol Number: Le.P.Re. Study | Start Date*: 2009-05-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. | |||||||||||||
Medical condition: Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia, [Hallek M et al, 2008]). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000243-10 | Sponsor Protocol Number: Hx-CD20-407 | Start Date*: 2007-05-16 | |||||||||||
Sponsor Name:Glaxo SmithKline Research and Development Limited | |||||||||||||
Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previ... | |||||||||||||
Medical condition: B-cell Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.